162 related articles for article (PubMed ID: 37628997)
1. Inhibition of USP2 Enhances TRAIL-Mediated Cancer Cell Death through Downregulation of Survivin.
Lee TG; Woo SM; Seo SU; Kim S; Park JW; Chang YC; Kwon TK
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628997
[TBL] [Abstract][Full Text] [Related]
2. Cepharanthine Enhances TRAIL-Mediated Apoptosis Through STAMBPL1-Mediated Downregulation of Survivin Expression in Renal Carcinoma Cells.
Shahriyar SA; Woo SM; Seo SU; Min KJ; Kwon TK
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30360403
[TBL] [Abstract][Full Text] [Related]
3. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
Woo SM; Min KJ; Seo SU; Kim S; Kubatka P; Park JW; Kwon TK
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269715
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-Specific Protease 2 in the Ventromedial Hypothalamus Modifies Blood Glucose Levels by Controlling Sympathetic Nervous Activation.
Hashimoto M; Fujimoto M; Konno K; Lee ML; Yamada Y; Yamashita K; Toda C; Tomura M; Watanabe M; Inanami O; Kitamura H
J Neurosci; 2022 Jun; 42(23):4607-4618. PubMed ID: 35504726
[TBL] [Abstract][Full Text] [Related]
5. Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.
Davis MI; Pragani R; Fox JT; Shen M; Parmar K; Gaudiano EF; Liu L; Tanega C; McGee L; Hall MD; McKnight C; Shinn P; Nelson H; Chattopadhyay D; D'Andrea AD; Auld DS; DeLucas LJ; Li Z; Boxer MB; Simeonov A
J Biol Chem; 2016 Nov; 291(47):24628-24640. PubMed ID: 27681596
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5.
Woo SM; Kim S; Seo SU; Kim S; Park JW; Kim G; Choi YR; Hur K; Kwon TK
Cell Death Dis; 2022 Sep; 13(9):821. PubMed ID: 36153316
[TBL] [Abstract][Full Text] [Related]
7. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Yoo J; Lee YJ
Mol Pharmacol; 2007 Dec; 72(6):1586-92. PubMed ID: 17848598
[TBL] [Abstract][Full Text] [Related]
8. Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.
Tse AK; Cao HH; Cheng CY; Kwan HY; Yu H; Fong WF; Yu ZL
J Invest Dermatol; 2014 May; 134(5):1397-1407. PubMed ID: 24213373
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of DR5 and Downregulation of Survivin by IITZ-01, Lysosomotropic Autophagy Inhibitor, Potentiates TRAIL-Mediated Apoptosis in Renal Cancer Cells via Ubiquitin-Proteasome Pathway.
Shahriyar SA; Seo SU; Min KJ; Kubatka P; Min DS; Chang JS; Kim DE; Woo SM; Kwon TK
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825566
[TBL] [Abstract][Full Text] [Related]
10. Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules.
Taniguchi H; Horinaka M; Yoshida T; Yano K; Goda AE; Yasuda S; Wakada M; Sakai T
Mol Cancer Ther; 2012 Oct; 11(10):2294-300. PubMed ID: 22784708
[TBL] [Abstract][Full Text] [Related]
11. [Effects of Ubiquitination on the Expression of BCL6 Protein，Cell Proliferation and Apoptosis in K562/G01 Cells].
Tang HM; Ding W; Ding YH; Wu JJ; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):379-384. PubMed ID: 30998141
[TBL] [Abstract][Full Text] [Related]
12. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
[TBL] [Abstract][Full Text] [Related]
13. Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation.
Woo SM; Seo SU; Kubatka P; Min KJ; Kwon TK
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31817770
[TBL] [Abstract][Full Text] [Related]
14. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
15. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
Kim JY; Kim EH; Kim SU; Kwon TK; Choi KS
Carcinogenesis; 2010 Mar; 31(3):367-75. PubMed ID: 19939880
[TBL] [Abstract][Full Text] [Related]
16. Tunicamycin enhances TRAIL-induced apoptosis by inhibition of cyclin D1 and the subsequent downregulation of survivin.
Zhang HY; Du ZX; Liu BQ; Gao YY; Meng X; Guan Y; Deng WW; Wang HQ
Exp Mol Med; 2009 May; 41(5):362-9. PubMed ID: 19307757
[TBL] [Abstract][Full Text] [Related]
17. Cullin 2-RBX1 E3 ligase and USP2 regulate antithrombin ubiquitination and stability.
Xu D; Wu J; Chen J; Jiang L; Chen J; Bao W; Chen X; Yang Q; Zhang X; Yao L; Su H; Liu J
FASEB J; 2021 Aug; 35(8):e21800. PubMed ID: 34324733
[TBL] [Abstract][Full Text] [Related]
18. A moderate static magnetic field enhances TRAIL-induced apoptosis by the inhibition of Cdc2 and subsequent downregulation of survivin in human breast carcinoma cells.
Lin T; Wan L; Qi X; Shi W; Lin J
Bioelectromagnetics; 2014 Jul; 35(5):337-46. PubMed ID: 24619849
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
Panner A; Crane CA; Weng C; Feletti A; Fang S; Parsa AT; Pieper RO
Cancer Res; 2010 Jun; 70(12):5046-53. PubMed ID: 20484045
[TBL] [Abstract][Full Text] [Related]
20. Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity.
Raviv Z; Zilberberg A; Cohen S; Reischer-Pelech D; Horrix C; Berger MR; Rosin-Arbesfeld R; Flescher E
Br J Pharmacol; 2011 Nov; 164(5):1433-44. PubMed ID: 21486277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
